EXPLORING the prophylactic potential of Azadirachta indica leaf extract against dyslipidemia.

ETHNOPHARMACOLOGICAL RELEVANCE: Several studies revealed that different parts of Azadirachta indica A. Juss, has therapeutic potential against inflammatory issues and dyslipidemia which is a major contributing cause to cardiovascular diseases, oxidative stress and serum glucose levels, etc. AIM OF STUDY: Present study was conducted to evaluate anti-dyslipidemic capacity of Azadirachta indica leaf extract in dyslipidemic rabbits. MATERIALS AND METHODS: Ethanolic extract of Azadirachta indica leaves was obtained by using Soxhlet apparatus. This extract was used for efficacy study on rabbits. In this context, 25 healthy rabbits were selected for study, Efficacy trial involved five groups of rabbits, 5 rabbits in each group; NC (Negative Control); healthy rabbits received normal diet. In remaining 20 rabbits, dyslipidemia was induced by using high fat diet for 28 days followed by administration of Azadirachta indica leaf ethanolic extract for 60 days in a dose-dependent manner. PC (Positive Control) include dyslipidemic rabbits received normal diet while G1, G2, G3 groups included dyslipidemic rabbits receiving different concentrations of Azadirachta indica leaf extract (i.e. 300, 500 and 700 mg/kg of body weight, respectively). Blood samples were analyzed for serum lipid profile after every 15 days to determine the effect of treatments. RESULTS: Significant reduction in total cholesterol (60 ± 3.4 mg/dL), triglycerides (40.31 ± 2.5 mg/dL) and low-density lipoprotein (28.87 ± 2.1 mg/dL) was observed in G2 (P ≤ 0.05)while a significant increase was observed in high-density lipoprotein (60.47 ± 1.7 mg/dL) of G2 (P ≤ 0.05) as compared to other groups. CONCLUSION: Results revealed that ethanolic extract of Azadirachta indica leaves in G2 group (@ 500 mg/kg of body weight) normalized lipid profile in dyslipidemic rabbits after 60 days of extract administration which significantly lowered TC, TG, LDL levels (P ≤ 0.05) and improved HDL level.

Comprehensive analysis of fatty acids in human milk of four Asian countries.

Human milk lipids provide not only energy but also indispensable bioactive components such as essential fatty acids. To establish the recommended daily intake value and guidelines for infant formula, a reference library of fatty acid composition has been generated from 4 Asian countries (South Korea, China, Vietnam, and Pakistan). Regardless of country, palmitic acid (C16:0), linoleic acid (C18:1), and linolenic acid (C18:2) were the 3 most abundant fatty acids in human milk and account for more than 75% of total fatty acids (total FA). However, there were several considerable differences between fatty acids, particularly n-3 and n-6 (omega-3 and omega-6) groups. Chinese mothers' milk had a high concentration of linoleic acid at 24.38 ± 10.02% of total FA, which may be due to maternal diet. Among the 4 countries, Pakistani mothers' milk contained a high amount of saturated fatty acid (56.83 ± 5.96% of total FA), and consequently, polyunsaturated fatty acids, including n-3 and n-6, were significantly lower than in other countries. It is noteworthy that docosahexaenoic acid (DHA) in Pakistani mothers' milk was 44.8 ± 33.3 mg/L, which is only 25 to 30% of the levels in the other 3 countries, suggesting the need for DHA supplementation for infants in Pakistan. Moreover, the ratio of n-6 to n-3 was also remarkably high in Pakistani mothers' milk (15.21 ± 4.96), being 1.4- to 1.7-fold higher than in other countries. The average DHA:ARA ratio in Asian human milk was 1.01 ± 0.79. Korean mothers' milk showed a high DHA:ARA ratio, with a value of 1.30 ± 0.98, but Pakistani mothers' milk had a significantly lower value (0.42 ± 0.12). The fatty acid compositions and anthropometric data of mother (body mass index, age) did not show any correlation. The obtained data might provide information about human milk compositions in the Asian region that could benefit from setting up recommended nutrient intake and infant formula for Asian babies.